ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Anixa Biosciences Inc
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026
$2.61−0.06 (-2.25%)
Close on Oct 19, 2026
- Market cap
- $89.22M
- P/E (TTM)
- –
- Dividend yield
- –
Anixa Biosciences Inc revenue by segment
By business segment
| Operating income | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 |
|---|---|---|---|---|
| Other [Member] | -$41.00K | -$38.00K | -$37.00K | -$54.00K |
| CAR-T Therapeutics [Member] | -$4.01M | -$4.21M | -$4.27M | -$4.45M |
| Cancer Vaccines [Member] | -$7.13M | -$6.63M | -$6.93M | -$7.39M |
By product or service
By region
From the segment and revenue-disaggregation notes of Anixa Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.